According to a new report by Polaris Market Research, the global hereditary testing market was valued at USD 7.73 billion in 2024 and is projected to reach USD 17.13 billion by 2034, expanding at a CAGR of 8.3% over the forecast period. Growth is underpinned by increased regulatory support for genetic testing, expansion of precision medicine initiatives, and rapid advancements in next-generation sequencing technologies.

What Is Driving Hereditary Testing Market Growth?

Demand is climbing as rapid advancements in genetic testing technologies converge with increasing awareness and acceptance of personalized medicine. Healthcare providers are prioritizing early disease detection and risk assessment, pushing hereditary testing adoption across hospitals, research institutions, and direct-to-consumer channels. Polaris analysts note that supportive government initiatives such as the Genetic Information Nondiscrimination Act position the market for sustained growth through 2034, with the molecular testing segment emerging as the largest revenue contributor and the ovarian cancer disease segment posting notable incremental gains.

Key Trends Shaping the Hereditary Testing Industry

AI-Driven Genomic Data Analysis

AI accelerates genomic data analysis, identifying hereditary risk factors with greater accuracy, while machine learning models detect rare genetic variants that conventional testing methods may overlook — a product innovation trend enabling more personalized risk assessments.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/hereditary-testing-market

Advancements in Next-Generation Sequencing

Innovations such as next-generation sequencing have enhanced the accuracy, speed, and cost-effectiveness of genetic analyses, expanding the scope of hereditary testing applications and enabling comprehensive screening for a broader range of genetic disorders.

Growing Direct-to-Consumer Genetic Testing Adoption

Rising consumer awareness and accessibility of at-home genetic tests are expanding market reach, a trend reinforced by companies integrating multi-omics approaches and expanding test portfolios to include rare hereditary conditions.

Market Segmentation: Breaking Down the Hereditary Testing Market

Polaris segments the hereditary testing market by technology, sample type, disease type, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Technology

The molecular testing segment dominated the market in 2024, attributed to the widespread adoption of techniques such as next-generation sequencing and polymerase chain reaction, which offer high accuracy and efficiency in detecting genetic mutations.

By Sample Type

The blood segment held the largest market share in 2024 due to the reliability and ease of collection associated with blood samples, while saliva is gaining traction as a non-invasive alternative favored in direct-to-consumer testing.

By Disease Type

Breast cancer testing dominated the market share in 2024, driven by the availability of well-established genetic tests such as BRCA1 and BRCA2 mutation analyses, while the ovarian cancer segment is experiencing significant growth as genetic predisposition awareness rises.

Regional Outlook: Where Is the Hereditary Testing Market Growing Fastest?

North America accounted for a major market share in 2024, driven by a strong presence of hereditary testing providers, advanced healthcare infrastructure, and well-established regulatory frameworks supporting clinical adoption. Asia Pacific is experiencing rapid growth, driven by rising healthcare investments, expanding genomic research, and increasing government support for genetic testing infrastructure in countries such as China, Japan, and India.

Competitive Landscape: Leading Hereditary Testing Companies

Key players profiled in the report include Myriad Genetics, Inc., Illumina, Inc., Natera, Inc., and Laboratory Corporation of America Holdings, who are focusing on research collaborations and strategic partnerships to strengthen their market position across the molecular testing and breast cancer segments outlined above. Recent moves include GeneDx's June 2025 partnership with Galatea Bio and Fabric Genomics to provide integrated hereditary cancer testing panels enhanced with polygenic risk scores, and Foundation Medicine's February 2025 plans to introduce two new germline tests identifying genetic variants linked to hereditary cancers.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the hereditary testing market forecast, this report benchmarks market share, segment-level pricing, and forecast data — by technology, sample type, disease type, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking direct-to-consumer genetic testing as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Pea Protein Market

Fogless Mirror Market

Allergy Diagnostics Market

Baking enzymes market

Fogless Mirror Market

Photoacoustic Tomography Market

Data Annotation Tools Market

Inulin Market

Industrial Cooling Systems Market